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We  map  all  ﬁve  missense  SNCA  mutations  on the  proposed  -synuclein  protein  models.
4 mutations  cluster  around  the  protein  loop  linking  the  two  legs  of  the  hairpin.
4 mutations  cluster  around  the  point  of hairpin  convergence  for  tetramer  formation.
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a  b  s  t  r  a  c  t
With  the  recent  identiﬁcation  of  two new  pathogenic  mutations  in -synuclein,  we map  the ﬁve  known
pathogenic  mutations  onto  the best  available  models  of the  protein  structure.  We  show  that  four  of  the
ﬁve  mutations  map  to  a potential  fold  in the  protein  with  the  exception  being  the  A30P  mutation  inccepted 27 April 2013
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which  the substitution  would  be expected  to  have  a profound  effect  on protein  structure.  We  discuss  this
localisation  in  terms  of  the  proposed  mechanisms  for mutation  pathogenicity.
© 2013 The Authors. Published by Elsevier Ireland Ltd. All rights reserved.arkinson’s disease
utations in -synuclein (SNCA) are a rare cause of autosomal dom-
nant Parkinson’s disease (PD) accounting for a small proportion
f familial cases [20]. To date, whole gene multiplications have
een discovered to cause the disease [6,19,37], together with a
ew missense mutations. These missense mutations include A53T
34], A30P [29] and E46K [43]. Additionally, we  and others have
ecently described two new mutations in PD cases: H50Q [1,35]
nd G51D [27,30]. The mechanism with which these SNCA point
utations initiate the disease cascade remains unknown, in con-
rast to whole gene multiplications which are likely to cause disease
imply through increased production of -synuclein [14]. Two pos-
ible hypotheses have been proposed to explain the pathogenicity
f point mutations mainly drawing from evidence provided from
athological studies [5,28,31], studies on cell and mouse models
9,42], and most recently from in vitro biophysical studies [7,18].
 This is an open-access article distributed under the terms of the Creative Com-
ons Attribution-NonCommercial-No Derivative Works License, which permits
on-commercial use, distribution, and reproduction in any medium, provided the
riginal author and source are credited.
∗ Corresponding author. Tel.: +44 (0)207 679 4297; fax: +44 (0)207 833 1017.
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304-3940/$ – see front matter ©  2013 The Authors. Published by Elsevier Ireland Ltd. Al
ttp://dx.doi.org/10.1016/j.neulet.2013.04.058These are the “permissive templating” hypothesis [23,26] and the
“autophagy impairment” hypothesis [32,36].
The tertiary and quaternary structures formed by -synuclein,
which could provide some insight into the pathogenic mecha-
nism associated to point mutations, remain a subject of debate
[4,10,17,21]. Some evidence suggests that -synuclein consists of
two antiparallel -helices linked through a short protein chain [39]
that naturally assembles into tetramers presumably preventing
-synuclein monomer aggregation [2,13,38,41]. Though conclu-
sive evidence has not been found, this suggestion may  provide
insight into the pathogenesis of PD [2]. The recent identiﬁca-
tion of the new mutations located at residues 50 [1,35] and 51
[27,30], closely adjacent to the original Contursi kindred mutation
at codon 53 [34] prompted us to map  them on the putative ter-
tiary structure of the -synuclein molecule suggested by Ulmer
et al. (http://dx.doi.org/10.2210/pdb1xq8/pdb) [39] in an attempt
to gain further insight into regions that are potentially crucial
for the molecule’s pathogenic potential. We  were stimulated to
do this by the clear evidence that the distribution of pathogenic
mutations in amyloid precursor protein (APP) and presenilin in
Alzheimer’s disease gives insight into their mode of pathogenicity
[24,25].
Clearly, all 5 SNCA point mutations cluster in proximity to the
short protein loop connecting the two  -helices, with 3 mutations
l rights reserved.
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Fig. 1. Tertiary structure for -synuclein based on the mode proposed by Ulmer et al.
[39]. The location of all missense mutations is depicted in red. Image generated using
the  chimera modelling program (http://www.cgl.ucsf.edu/chimera/) using PDB data
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presented by the fact that some of these critical residues, including
F
d
v
Sor  -synuclein reference 1XQB. (For interpretation of the references to colour in
gure legend, the reader is referred to the web  version of the article.)
ocated on the longer arm of the -synuclein molecule and 1 on the
horter in roughly mirroring positions, and with the E46K, H50Q,
nd A53T mutations aligning across the exterior of the second a-
elix [8] (Fig. 1). Although the A30P mutation is further away from
his loop, the effect of the proline amino acid substitution has the
otential to cause greater disruption to the folding of -synuclein
han the other amino acid substitutions.
This clustering of mutations close to the protein loop in
ombination with the very limited benign sequence vari-
bility (Exome Variant Server, NHLBI ESP, Seattle, WA [URL:
vs.gs.washington.edu/EVS/] [accessed on 10/2012]) and asso-
iated tolerance to conformational variations of -synuclein
ndicate the importance of this region and consecutively of the
airpin formation [39] for the molecule’s function. Our observation
ould also be consistent with the suggested tetramer model for
-synuclein (Fig. 2). The hairpin structure appears to be critical for
he establishment of appropriate intermolecular interactions for
he tetramer formation [41]; we speculate that point mutations
isrupting this hairpin conformation directly disrupt the inher-
ntly fragile tetramer and make the freely ﬂoating -synuclein
onomers susceptible to oligomerisation and aggregation, with a
oncomitant involvement of the proteasomal degradation system
9,42]. Thus, point mutations and whole gene multiplications
ould cause PD through 2 distinct mechanisms (impaired oligomer
equestration into protein tetramers in the former and increased
ig. 2. Model structure for -synuclein modiﬁed from published solution NMR  data [41]
isease-associated amino acid locations in red, presented as stick models. (For interpreta
ersion of the article.)
ource: Courtesy of T. Pochapsky (Brandeis), T. Bartels and D. Selkoe (Harvard Medical Schtters 546 (2013) 67– 70
template production in the latter case) with the same endpoint:
the formation of -synuclein aggregates in the form of Lewy bodies
and Lewy neurites.
The clustering of three mutation sites in the region of four his-
tidines with metal binding properties [11] within the core of the
putative tetramer (Fig. 2) could indicate the presence of a binding
pocket. Studies of soluble -synuclein monomers have demon-
strated that these associate to Cu2+ through their N-terminal two
residues [12] and the codon 50 harbouring the sole histidine residue
in the open reading frame of -synuclein [3,15,16,35] with folding
of the protein around Cu2+ seemingly disrupted by the H50Q muta-
tion [35]. As no studies have been conducted on tetramer binding
of small molecules/protein interactors to date, it might be the case
that the nature of these interactions is altered in the context of the
tetramer. Thus, further adding to our suggested model, it is possible
that disruption of such small molecule binding by familial PD SNCA
mutations could contribute to the instability of the tetramer.
The variability in clinical presentation and pathology associated
to each speciﬁc mutation could correspond to the degree of the
hairpin and tetramer disruption and thus quantity of -synuclein
monomers available for aggregation; if this is indeed the case, the
G51D mutation represents the most deleterious of all 5 mutations
resulting in a disease reminiscent of the one caused by the whole
gene triplication [22,27,33], whereas the A30P mutation (interest-
ingly the only one located on the short helix) is the most “benign”
[20,29]. Even though the H50Q mutation is adjacent to the severe
G51D and A53T mutations, the associated clinical presentation is
equivalent to the more mild phenotype associated with the A30P
mutation [35]; although our proposed model does not offer a sat-
isfactory explanation for this discrepancy, the location of residue
H50 at the start of the second a-helix [41] could be relevant. It is
also possible that employment of alternative metals such as zinc
(which can weakly bind to H50) [40] to compensate for this codon
substitution could attenuate the clinical features associated to this
mutation. This hypothesis could also explain the apparent paradoxthe A53 residue, are not well conserved, as a substantial propor-
tion of higher order mammals carry the human disease causing
residue T in codon 53 (though the lack of conservation could also
 in two different projections. Ribbon presentation of an -synuclein tetramer with
tion of the references to colour in ﬁgure legend, the reader is referred to the web
ool).
E. Kara et al. / Neuroscience Letters 546 (2013) 67– 70 69
F he loc
u
b
c

(
e
s
s
a
m
e
b
A
i
e
P
t
S
P
P
M
m
b
(
w
v
t
(
W
R
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[ig. 3. Conservation diagram of human ,  and  synuclein molecules depicting t
sing  the basic local alignment search tool (BLAST, http://blast.ncbi.nlm.nih.gov).
e attributed to lifespan differences between species). Similarly,
odons 50, 51 and 53 are not well conserved between ,  and
 synuclein which are otherwise highly homologous molecules
Fig. 3) thus again raising the possibility of metal binding differ-
nces. Alternatively, conformational differences or the absence of
uch elegant tertiary and/or quaternary SNCA structures in other
pecies and/or homologue molecules could explain these discrep-
ncies. Clearly, the key to the understanding of the pathogenetic
echanism and signiﬁcance of these point mutations would be the
lucidation of the tertiary and quaternary structure of -synuclein
oth in humans and other species.
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